CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Daiichi Sankyo

DSKYF
$34.76BLarge Cap

Next catalyst

Phase 2December 2026

Trastzumab Deruxtecan

Ovarian Cancer

Get an email about DSKYF's next catalysts

Track Daiichi Sankyo (DSKYF) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 19 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline

Catalyst Timeline

20 upcoming, 0 past

Phase 2Next

Trastzumab Deruxtecan Phase 2 Est. Readout (TROY)

December 2026~Trastzumab Deruxtecan116

Estimated primary completion for Trastzumab Deruxtecan trial (NCT07340164) in Ovarian Cancer. Topline data typically follows completion by weeks to months.

Source
Phase 2

Trastuzumab Deruxtecan Phase 2 Est. Readout

December 2026~Trastuzumab Deruxtecan88

Estimated primary completion for Trastuzumab Deruxtecan trial (NCT04553770) in Early-stage Breast Cancer. Topline data typically follows completion by weeks to months.

Source
Phase 3

Dato-DXd Phase 3 Est. Readout (TROPION-Lung15)

January 2027~Dato-DXd768

Estimated primary completion for Dato-DXd trial (NCT06417814) in Metastatic Non-small Cell Lung Cancer. Topline data typically follows completion by weeks to months.

Source
Phase 2

DS-5141b Phase 2 Est. Readout

January 2027~DS-5141b8

Primary completion for DS-5141b trial (NCT04433234) in Duchenne Muscular Dystrophy

Source
Phase 2

Trastuzumab deruxtecan Phase 2 Est. Readout

February 2027~Trastuzumab Deruxtecan127

Estimated primary completion for Trastuzumab deruxtecan trial (NCT06271837) in Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer). Topline data typically follows completion by weeks to months.

Source
Phase 2

Trastuzumab deruxtecan Phase 2 Est. Readout (DPT02)

March 2027~Trastuzumab Deruxtecan477

Estimated primary completion for Trastuzumab deruxtecan trial (NCT04482309) in Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer. Topline data typically follows completion by weeks to months.

Source
Phase 2

U3-1402 Phase 2 Est. Readout (ICARUS BREAST)

April 2027~U3-1402139

Estimated primary completion for U3-1402 trial (NCT04965766) in Metastatic Breast Cancer. Topline data typically follows completion by weeks to months.

Source
Phase 2

Ifinatamab deruxtecan (I-DXd) Phase 2 Est. Readout

April 2027~Ifinatamab deruxtecan (I-DXd)247

Primary completion for Ifinatamab deruxtecan (I-DXd) trial (NCT04145622) in Advanced Solid Tumor

Source

How DSKYF's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQHealthcare🇺🇸North America20.2K employees
Drug Pipeline

Salvage Chemotherapy

Phase 3

AML

olmesartan medoxomil + amlodipine + hydroclororthiazide

Phase 3

Essential Hypertension

OLM -AML -Hydrochlorothiazide

Phase 3

Essential Hypertension

Olmesartan -Amlodipine -Hydrochlorothiazide

Phase 3

Essential Hypertension

cevimeline hydrochloride

Phase 3

Head and Neck Cancer

low molecular weight heparin/unfractionated heparin

Phase 3

Venous Thromboembolism

enoxaparin sodium

Phase 3

Venous Thromboembolism

CHS-0214

Phase 3

Rheumatoid Arthritis

T-DXd

Phase 3

Advanced Cancer

Rivoglitazone

Phase 3

Type 2 Diabetes

Tivantinib

Phase 3

Metastatic Colorectal Cancer

exatecan mesylate

Phase 3

Esophageal Cancer

ofloxacin otic

Phase 3

Otitis Media

Denosumab

Phase 3

Osteoporosis

Colesevelam HCl

Phase 3

Type 2 Diabetes

DS-1062a

Phase 3

Non-small Cell Lung Cancer

CPT-11 and TS-1

Phase 3

Colorectal Cancer

Dato-DXd

Phase 3

Urothelial Cancer

gemcitabine hydrochloride

Phase 3

Pancreatic Cancer

Warfarin Potassium

Phase 3

CTEPH

Hydrochlorothiazide

Phase 3

Hypertension

prasugrel

Phase 3

Diabetes Mellitus

Quizartinib

Phase 3

Leukemia

Pemetrexed

Phase 3

Metastatic Non Small Cell Lung Cancer

Pioglitazone

Phase 3

Type 2 Diabetes Mellitus

Low molecular weight heparin

Phase 3

Venous Thromboembolism (VTE)

warfarin tablets

Phase 3

Stroke

Etoposide

Phase 3

Non-small Cell Lung Cancer

Clopidogrel

Phase 3

Peripheral Arterial Disease

Pregabalin

Phase 3

Pain Associated With Fibromyalgia

Nab-paclitaxel

Phase 3

Breast Cancer

Datopotamab Deruxtecan

Phase 3

Metastatic Non Small Cell Lung Cancer

DS-8201a

Phase 3

Neoplasm, Gastrointestinal

Pexidartinib

Phase 3

Tenosynovial Giant Cell Tumor

edoxaban

Phase 3

Prevention

DS-5565

Phase 3

Pain Associated With Fibromyalgia

Trastuzumab Deruxtecan

Phase 3

Gastric Cancer

olmesartan medoxomil + hydrochlorothiazide, if necessary

Phase 3

Essential Hypertension

Ramucirumab

Phase 3

Non-Small Cell Lung Cancer

OM 40

Phase 3

Hypertension

CS-3150

Phase 3

Essential Hypertension

OM/HCTZ 40/12.5

Phase 3

Hypertension

Welchol

Phase 3

Type 2 Diabetes Mellitus

DU-176b

Phase 3

Venous Thromboembolism

CS-8958

Phase 3

Influenza, Human

Patritumab Deruxtecan

Phase 3

Nonsquamous Non-small Cell Lung Cancer

Trastuzumab deruxtecan (DS-8201a)

Phase 3

Breast Cancer

olmesartan medoxomil + hydrochlorothiazide

Phase 3

Essential Hypertension

Ifinatamab deruxtecan

Phase 3

Esophageal Squamous Cell Carcinoma

olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)

Phase 3

Essential Hypertension

Trastuzumab deruxtecan (T-DXd)

Phase 3

Breast Cancer

Eplerenone

Phase 3

Essential Hypertension

Chemotherapy

Phase 3

Acute Myeloid Leukemia

Vitamin K antagonist

Phase 3

Atrial Fibrillation

Dalteparin

Phase 3

Venous Thromboembolism (VTE)

Mirogabalin

Phase 3

Diabetic Peripheral Neuropathic Pain

Eribulin

Phase 3

Breast Cancer

R-DXd

Phase 3

Solid Cancer

Amrubicin

Phase 3

Small Cell Lung Cancer

Olmesartan medoxomil plus amlodipine

Phase 3

Hypertension

Edoxaban-based Regimen

Phase 3

Atrial Fibrillation

Transdermal Patch

Phase 3

Trauma

nitrendipine + hydrochlorothiazide, if necessary

Phase 3

Isolated Systolic Hypertension

ASA

Phase 3

SCAD

olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets

Phase 3

Essential Hypertension

Eribulin mesylate

Phase 3

Breast Cancer

Metformin HCl tablets and Colesevelam tablets

Phase 3

Type 2 Diabetes Mellitus

Colesevelam hydrochloride

Phase 3

Type 2 Diabetes

olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets

Phase 3

Essential Hypertension

olmesartan medoxomil/hydrochlorothiazide tablets

Phase 3

Essential Hypertension

Platinum Chemotherapy

Phase 3

Non-small Cell Lung Cancer

Edoxaban tablets (low dose regimen-30mg)

Phase 3

Stroke

Edoxaban tablets (high dose regimen-60mg)

Phase 3

Stroke

Olmesartan medoxomil - Amlodipine

Phase 3

Essential Hypertension

Olmesartan medoxomil tablets high dose

Phase 3

Metabolic Syndrome

DU-176b (edoxaban)

Phase 3

Venous Thromboembolism

VKA-Based Regimen

Phase 3

Atrial Fibrillation

losartan potassium

Phase 3

Essential Hypertension

Olmesartan medoxomil tablets low dose

Phase 3

Metabolic Syndrome

T-DM1

Phase 3

HER2-Positive Primary Breast Cancer

Colesevelam

Phase 3

Type 2 Diabetes

edoxaban tosylate(DU-176b)

Phase 3

Venous Thromboembolism

Olmesartan medoxomil

Phase 3

Atherosclerosis

olmesartan medoxomil + amlodipine

Phase 3

Essential Hypertension

I-DXd

Phase 2

Oesophageal Squamous Cell Carcinoma

Combination drug

Phase 2

Hematological Malignancies

Patritumab Deruxtecan (Fixed dose)

Phase 2

Non-Small Cell Lung Cancer Metastatic

Carperitide

Phase 2

Heart Failure, Congestive

DS-5670a

Phase 2

Covid19

DU-176b tablets

Phase 2

Atrial Fibrillation

soblidotin

Phase 2

Lung Cancer

VN-0200

Phase 2

Respiratory Syncytial Virus Infections

DS-3939a

Phase 2

Advanced Solid Tumor

Valemetostat Tosylate

Phase 2

Adult T-cell Leukemia/Lymphoma

Quizartinib High Dose

Phase 2

Acute Myeloid Leukemia

DS-1040b

Phase 2

Acute Ischemic Stroke

DS-1001b

Phase 2

WHO Grade II Glioma

AC220

Phase 2

Leukemia, Myeloid, Acute

Compound AC220

Phase 2

Acute Myeloid Leukemia

Ifinatamab deruxtecan (I-DXd)

Phase 2

Advanced Solid Tumor

CS-1008 (humanized anti-DR5 antibody)

Phase 2

Pancreatic Cancer

DJ-927

Phase 2

Colorectal Cancer

U3-1287

Phase 2

NSCLC (Advanced Non-small Cell Lung Cancer)

PLX3397

Phase 2

Hodgkin Lymphoma

Rivoglitazone HCl

Phase 2

Type 2 Diabetes

Raludotatug deruxtecan

Phase 2

Advanced Solid Tumor

CS7017 tablets

Phase 2

Metastatic Non-small Cell Lung Cancer

DS-1211b

Phase 2

Pseudoxanthoma Elasticum

Pactimibe, CS-505

Phase 2

Coronary Heart Disease

CS7017

Phase 2

Colorectal Cancer

Warfarin potassium tablets

Phase 2

Atrial Fibrillation

edoxaban tosylate

Phase 2

Deep Vein Thrombosis

SUN13837 injection

Phase 2

Acute Spinal Cord Injury

Edoxaban (DU-176b)

Phase 2

Atrial Fibrillation

CS-1008

Phase 2

Non-small Cell Lung Cancer

HER3-DXd

Phase 2

Advanced Solid Tumor

DS-7011a

Phase 2

Systemic Lupus Erythematosus

ASB17061

Phase 2

Atopic Dermatitis

piclozotan

Phase 2

Parkinson's Disease

coformulation favezelimab/pembrolizumab

Phase 2

Small Cell Lung Carcinoma

MK-2010

Phase 2

Ovarian Cancer Recurrent

SUN13834

Phase 2

Atopic Dermatitis

DS-5141b

Phase 2

Duchenne Muscular Dystrophy

CS-917

Phase 2

Diabetes Mellitus, Type 2

DS-5565 tablet

Phase 2

Diabetic Peripheral Neuropathy

DS-1103a

Phase 2

Solid Tumor

Quizartinib Low Dose

Phase 2

Acute Myeloid Leukemia

DS3790a

Phase 2

Hematological Malignancies

SUN11031

Phase 2

Cachexia

DS-8500a

Phase 2

Type 2 Diabetes Mellitus

DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor

Phase 2

Thrombosis

Trastzumab Deruxtecan

Phase 2

Ovarian Cancer

U3-1402

Phase 2

Metastatic Breast Cancer

Abraxane + Tigatuzumab

Phase 2

Breast Cancer

Pregabalin capsules

Phase 2

Pain

FOLFOX

Phase 2

Malignant Solid Tumour

Trastuzumab deruxtecan + 5FU/LV

Phase 2

Esophagogastric Adenocarcinoma

Trastuzumab deruxtecan + FLO

Phase 2

Esophagogastric Adenocarcinoma

5-hydroxytryptamine subtype 3 receptor antagonist

Phase 2

Carcinoma, Non-Small-Cell Lung

Pharmacological intensification based on olmesartan

Phase 2

Ischemic Stroke

Enhertu

Phase 2

Prostate Cancer Metastatic

Valemetostat

Phase 2

Lymphoma

Neurokinin-1 receptor antagonist

Phase 2

Carcinoma, Non-Small-Cell Lung

Boserolimab

Phase 2

Carcinoma, Non-Small-Cell Lung

Patritumab Deruxtecan (Up-Titration)

Phase 2

Non-Small Cell Lung Cancer Metastatic

Vibostolimab

Phase 2

Carcinoma, Non-Small-Cell Lung

MK-4830

Phase 2

Carcinoma, Non-Small-Cell Lung

Sitagliptin

Phase 2

Type 2 Diabetes Mellitus

Trastuzumab Deruxtecan (T-DXd) monotherapy

Phase 2

Gastric Adenocarcinoma

T-DXd, Durvalumab and Capecitabine Combination

Phase 2

Gastric Adenocarcinoma

Rescue Medications

Phase 2

Gastroesophageal Junction

89Zr-Patritumab deruxtecan

Phase 2

Non-Small Cell Lung Carcinoma

Abraxane alone

Phase 2

Breast Cancer

efatutazone

Phase 2

Anaplastic Thyroid Cancer

MK-1084

Phase 2

Lung Neoplasm Malignant

Gocatamig

Phase 2

Small Cell Lung Cancer Extensive Stage

Intrathecal (IT) triple chemotherapy prophylaxis

Phase 2

Acute Myeloid Leukemia

Dexrazoxane

Phase 2

Acute Myeloid Leukemia in Children

irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)

Phase 2

Colorectal Cancer

CS-7017

Phase 2

Advanced Non-small Cell Lung Cancer (NSCLC)

Frequently asked questions

What is in Daiichi Sankyo's drug pipeline?→

CatalystAlert tracks 160 drug candidates in Daiichi Sankyo's (DSKYF) pipeline across Phase 3, Phase 2. Its lead program is Trastuzumab Deruxtecan (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Daiichi Sankyo's next FDA catalyst?→

Daiichi Sankyo's (DSKYF) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track DSKYF biotech catalysts?→

Add DSKYF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Daiichi Sankyo's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply